Glucocorticoid-remediable aldosteronism (GRA) is a form of hypertension which is transmitted as an autosomal dominant. The syndrome is characterised by hyperaldosteronism, hypokalaemia and low plasma renin activity. These abnormalities can be corrected with low-dose glucocorticoid therapy.
Non-reciprocal recombination between the 11␤-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes creates a chimaeric gene which has 5′ regulatory elements of CYP11B1 spliced to CYP11B2 sequences. GRA is caused by the high-level expression of this mutant form of CYP11B2 under the influence of adrenocorticotrophin instead of angiotensin II. 1 GRA is thought to be uncommon in Caucasians. However, patients with GRA have variable clinical features (for instance, hypokalaemia may be less common than previously thought) 2 so the true prevalence of the disease is unknown. Furthermore, the prevalence of GRA may vary between ethnic groups. We have used a modification of a recentlydescribed PCR method 3 to directly test for GRA in a sample of Jamaican hypertensives.
Subjects were identified as part of a larger study of the genetic determinants of essential hypertension at the University Hospital of the West Indies, Kingston, Jamaica. This sample comprises 117 unrelated subjects diagnosed as having essential hypertension before the age of 50 (mean blood pressure = 156/93 mm Hg, mean body mass index = 28 kg/m 2 ). PCR reactions were set up in parallel. Mix 1 contained a forward primer specific for the 5′ untranslated region (UTR) of CYP11B2, Mix 2 contained a forward primer specific for the 5′-UTR of CYP11B1. Both mixes contained a reverse primer which was specific for intron 5 of CYP11B2. These primers thus encompassed all of the breakpoints described to date. PCR reactions were performed using 100 ng DNA, 10 nmol of each dNTP, 15 pmol of each of the appropriate oligonucleotide primer pairs and 2U each of AmpliTaq (Perkin-Elmer, CA, USA) and Taq Extender additive (Stratagene, CA, USA) in a total volume of 50 l 1X Taq extender buffer (Stratagene) with 1.5 mM McCl 2 . A 'hot start' on a PTC-200 thermal cycler (MJ Research, MA, USA) was employed. An initial denaturation step of 94°C for 1.5 min was followed by 38 cycles of: 95°C for 30 sec, 68°C for 1 min and 72°C for 3.5 min, then a final extension step of 72°C for 10 min. If the chimaeric gene was present there would have been amplification in both mixes. However, the absence of the chimaeric gene results in amplification in Mix 1 only (Figure 1 ). Each PCR run included a positive control (kindly provided by Dr G Inglis, Glasgow). No chimaeric genes were identified.
Our sample of 117 individuals (234 chromosomes) would have had approximately 70% power to detect the GRA mutation even if it were present at a frequency as low as 0.005. 4 This is the first report of direct PCR screening for GRA in an Afro-Caribbean population. These data suggest that, as in Caucasians, GRA is unlikely to be a common cause of hypertension in Afro-Caribbean subjects. 
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